ReviewJournal of blood medicine2015
Acquired hemophilia A: emerging treatment options.
Review in Journal of blood medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- A Case Report on Emergency Medicine: Suspected Acquired Hemophilia A in an Older Adult Male.Cureus · 2026Article
- Orthopedic manifestations of acquired hemophilia: a case report on uncontrolled bleeding and progressive swelling post-phlebotomy- should fasciotomy be considered?BMC musculoskeletal disorders · 2025Article
- Article
- Spontaneous Subdural Hematomas as Initial Presentation of Acquired Coagulopathy: A Case Report.Cureus · 2025Article
- Standard dose and low-dose rituximab combined with glucocorticoids and cyclophosphamide in the treatment of acquired haemophilia A.Frontiers in immunology · 2025Article
- The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes.Frontiers in immunology · 2024Article
- A Rare Case of Acquired Factor VIII Inhibition in an Elderly Female.Journal of community hospital internal medicine perspectives · 2024Article
- Diagnostic Challenges and Management of Acquired Hemophilia A Presenting as Gross Hematuria: A Case Report.Cureus · 2023Article
- An Unusual Case of Bleeding: Acquired Hemophilia A.Cureus · 2023Article
- Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report.World journal of clinical cases · 2023Article
- Article
- Review
- Article
- Article
- How to manage bleeding disorders in aging patients needing surgery.Hematology. American Society of Hematology. Education Program · 2021Article
- Principles of care for acquired hemophilia.European journal of haematology · 2021Review
- The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A.Frontiers in medicine · 2021Review
- Diagnosis and Management of Acquired Hemophilia A: Case Reports and a Literature Review.Case reports in medicine · 2021Article
- Bilateral renal haematuria and obstructive renal failure from acquired haemophilia A: a medical cause for a surgical problem.BMJ case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor) to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe, potentially life-threatening hemorrhage. Disease management focuses on controlling bleeding, primarily with the use of bypassing therapy and recombinant porcine FVIII, and permanently eradicating the autoantibody using various immunosuppressants. Treatment challenges include delayed diagnosis, difficulty achieving hemostasis and durable remissions, and complications associated with the use of hemostatic and immunosuppressive therapy in a primarily older patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.